Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06151964). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 166 participants (ACTUAL). Conditions: Overweight and Obesity. Interventions: DRUG: AZD9550; DRUG: placebo; DRUG: AZD9550 and AZD6234. Primary outcome measures: Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study. , Day - 35 to Day 261; Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters. , Day - 35 to Day 261; Number and percentage of participants with clinically significant changes in ECG parameters. , Day - 35 to Day 261; Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters , Day - 35 to Day 261; Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Maximum observed concentration of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Time to maximum observed concentration of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Apparent oral clearance of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Apparent volume of distribution of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Ratio for AUC of AZD9550 following repeat weekly SC doses , Day 1 to Day 65; Ratio for Cmax of AZD9550 following repeat weekly SC doses , Day 1 to Day 65. Brief summary: AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its associated co-morbidities. Co-administration of AZD9550 and AZD6234 is currently being evaluated in participants living with obesity and overweight without T2DM in an ongoing Phase 2b study. The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 monotherapy in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body (Parts A-D). In addition, the study will investigate the safety and tolerability of co-administration of AZD9550 and AZD6234 in participants living with T2DM with obesity or overweight aged 18 through 75 years (Part E), and safety and tolerability for different titration regimens for AZD9550 in participants living with obesity, but without T2DM, aged 18 through 75 years (Part F).